

Vitamin D and chronic kidney disease

Chang Seong Kim and Soo Wan Kim

Department of Internal Medicine,
Chonnam National University
Medical School, Gwangju, Korea

Received: May 10, 2014

Accepted: May 23, 2014

Correspondence to
Soo Wan Kim, M.D.

Department of Internal
Medicine, Chonnam National
University Medical School, 42
Jebong-ro, Dong-gu, Gwangju
501-757, Korea
Tel: +82-62-220-6271
Fax: +82-62-225-8578
E-mail: skimw@chonnam.ac.kr

Chronic kidney disease (CKD) has been recognized as a significant global health problem because of the increased risk of total and cardiovascular morbidity and mortality. Vitamin D deficiency or insufficiency is common in patients with CKD, and serum levels of vitamin D appear to have an inverse correlation with kidney function. Growing evidence has indicated that vitamin D deficiency may contribute to deteriorating renal function, as well as increased morbidity and mortality in patients with CKD. Recent studies have suggested that treatment with active vitamin D or its analogues can ameliorate renal injury by reducing fibrosis, apoptosis, and inflammation in animal models; this treatment also decreases proteinuria and mortality in patients with CKD. These renoprotective effects of vitamin D treatment are far beyond its classical role in the maintenance of bone and mineral metabolism, in addition to its pleiotropic effects on extra-mineral metabolism. In this review, we discuss the altered metabolism of vitamin D in kidney disease, and the potential renoprotective mechanisms of vitamin D in experimental and clinical studies. In addition, issues regarding the effects of vitamin D treatment on clinical outcomes are discussed.

Keywords: Vitamin D; Renal insufficiency, chronic; Cardiovascular diseases; Mortality

INTRODUCTION

Chronic kidney disease (CKD) is characterized by a progressive loss of renal function that often leads to end-stage renal disease (ESRD), high risk for cardiovascular disease, and high mortality [1,2]. CKD is a growing global health problem due to increased prevalence worldwide. In the United States, the prevalence of CKD was estimated to be 11% based on data from the Third National Health and Nutrition Examination Survey (NHANES III) [3]. In Korea, the prevalence of CKD stage 3 to 5 was 7.7% in 2007 based on data from the Korean National Health and Nutrition Examination Survey [4]. Under current guidelines, the therapeutic strategies for patients with CKD include aggressive blood pressure control, and medications such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers,

and statins. However, despite these treatment options, individuals with CKD still have high rates of morbidity and mortality [1,5].

Over the years, studies have improved the understanding of the biological and clinical consequences of the interaction between disordered vitamin D metabolism and CKD. Vitamin D (e.g., 25-hydroxyvitamin D [$25(\text{OH})\text{D}_3$] and 1,25-dihydroxyvitamin D [$1,25(\text{OH})_2\text{D}_3$]) deficiencies are now becoming a global epidemic problem in both the general population and patients with CKD [6,7]. Several observational studies have demonstrated an important link between vitamin D deficiency, impaired glomerular filtration rate (GFR), and increased mortality in patients with CKD [8-10]. Moreover, activated vitamin D treatment reduces all-cause and cardiovascular mortality rates in patients with CKD and those undergoing hemodialysis [11,12]. The

critical role of the vitamin D endocrine system in disease prevention extends beyond the classic regulation of calcium and phosphorous homeostasis and skeletal integrity, to its potentially pleiotropic effects on extramineral metabolism, including kidney function.

This review focuses on the potential role of active vitamin D in the treatment of kidney disease beyond the correction of secondary hyperparathyroidism in patients with CKD. Therefore, we discuss altered vitamin D metabolism in kidney disease, and the potent renal protective mechanism of active vitamin D and its analogues in various animal models and patients with CKD.

ALTERED VITAMIN D METABOLISM IN KIDNEY DISEASE

Vitamin D is a steroid prohormone synthesized in the skin from cholesterol-derived precursors (i.e., 7-dehydrocholesterol) through a photochemical process. Alternatively, vitamin D can be obtained from various dietary sources such as fortified dairy products, fish oils, and mushrooms. Two native, biologically inactive, forms of vitamin D exist: vitamin D₃ (cholecalciferol), which is derived from the skin and animal products, and vitamin D₂ (ergocalciferol), which is of nonanimal origin [13]. These inactive forms are converted into their biologically active forms in the liver and kidney via two hydroxylation steps. The first step in the metabolic activation of vitamin D is metabolism to form 25-hydroxyvitamin D [25(OH)D] in the liver. This is the main storage and circulating form of vitamin D, and is therefore used as an indicator of vitamin D levels [14]. The second step occurs in the kidney, where 25(OH)D is converted to 1,25 dihydroxyvitamin D [1,25(OH)₂D] by the enzyme 1 α -hydroxylase, which is expressed primarily in the proximal tubular epithelial cells of the kidney [15]. However, this enzyme has been detected in extrarenal cells and tissues, including the prostate, breasts, colon, lungs, pancreatic β -cells, monocytes, endothelial cells, vascular smooth muscle cells, osteoblasts, and parathyroid cells [16]. This extra-renally produced 1,25(OH)₂D primarily functions as an autocrine or paracrine factor at these sites, and may play a role in various nonclassical actions of vitamin D [15,17].

The final step in the vitamin D metabolic pathway is its inactivation, a process catalyzed by 24-hydroxylase, resulting in catabolism of 1,25(OH)₂D and 25(OH)D into 1,24,25 trihydroxyvitamin D [1,24,25(OH)₃D], and ultimately into water-soluble calcitroic acid and the inactive blood metabolite 24,25(OH)₂D [13,18].

The kidney plays a central role in vitamin D metabolism and regulation of its circulating levels. Therefore, impaired renal function may lead to vitamin D deficiency, as has been observed in patients with CKD. There seem to be several mechanisms involved in decreased production of 1,25(OH)₂D that occur over the course of CKD progression. A decrease in renal mass limits the amount of 1 α -hydroxylase available for the production of the active vitamin D metabolite [19]. During the course of CKD, progressive decreases in GFR may also limit the delivery of 25(OH)D to 1 α -hydroxylase, resulting in reduced production of 1,25(OH)₂D [20]. However, even mild reductions in GFR cause 1,25(OH)₂D levels to fall, suggesting that another mechanism may explain the decreased levels of vitamin D metabolites associated with kidney disease.

The 25(OH)D bound to its carrier, the vitamin D-binding protein, is filtered through the glomerulus and absorbed into the proximal tubules by the receptor megalin [21,22]. Megalin is an endocytic receptor also responsible for the renal tubular reabsorption of albumin and other low molecular weight proteins [22]. Interestingly, megalin knockout mice develop low molecular weight proteinuria and lose large amounts of vitamin D/vitamin D binding protein in their urine, resulting in severe vitamin D deficiency and bone disease, despite sufficient delivery of substrates to the kidney proximal tubules [22,23]. Renal megalin is induced by active vitamin D and the vitamin D receptor (VDR) complex [24]. Therefore, vitamin D deficiency could result from decreased megalin, creating a vicious cycle for 25(OH)D uptake and active vitamin D production.

Another key factor that can induce low vitamin D status over the course of kidney disease is the increase in fibroblast growth factor 23 (FGF-23) levels, which can directly suppress the activity and expression of 1 α -hydroxylase [25,26]. Serum levels of FGF-23 increase with the decline in GFR and the increased phosphate level [27,28]. In addition, dietary phosphate intake decreases renal 1 α -hydroxylase activity and expression of its

messenger ribonucleic acid (mRNA), independently of changes in parathyroid hormone (PTH) and calcium levels [15,29]. Thus, persistent phosphate retention and increased FGF-23 due to declining kidney function may be a major mechanism contributing to the suppressed activation of 1α -hydroxylase, which decreases the levels of $1,25(\text{OH})_2\text{D}$. FGF-23 also upregulates expression of 24-hydroxylase, which decreases the concentration of circulating $1,25(\text{OH})_2\text{D}$ [30]. In addition to these factors, the activity of 1α -hydroxylase may also be suppressed by N-terminally truncated PTH fragments [31] or progressive retention of uremic toxins [31,32]. An overview of how vitamin D metabolism is altered during the course of kidney disease is depicted in Fig. 1.




Figure 1. Altered vitamin D metabolism in the course of kidney disease progression. In chronic kidney disease progression, decreased renal mass limits the amount of 1α -hydroxylase in renal proximal tubular cells. In addition, decreases in glomerular filtration rate (GFR) and low megalin content contribute to impaired $25(\text{OH})\text{D}$ uptake and protein reabsorption. Moreover, increased levels of serum level of phosphate (P), fibroblast growth factor 23 (FGF23), N-terminally truncated parathyroid hormone (PTH) fragments, and uremic toxins, along with kidney function decline may contribute to the suppressed activation of 1α -hydroxylase, resulting in decreased levels of $1,25(\text{OH})_2\text{D}$. Also, increased FGF23 upregulates the expression of 24-hydroxylase, resulting in the catabolism of $1,25(\text{OH})_2\text{D}$ to the inactive form of vitamin D, $1,24,25(\text{OH})_3\text{D}$. DBP, vitamin D binding protein; VDR, vitamin D receptor; IDBP3, intracellular vitamin D binding protein 3.

RENOPROTECTIVE MECHANISMS OF VITAMIN D IN EXPERIMENTAL STUDIES

Results from animal model studies have suggested the potential renoprotective effects of active vitamin D and its analogues (Table 1) [33-45]. Beyond its role in calcium and phosphate homeostasis, vitamin D is an important modulator of cellular proliferation, inflammation, differentiation, and immunity [33,46,47]. Vitamin D attenuates kidney injury by suppressing fibrosis, inflammation, and apoptosis, by inhibiting multiple pathways known to play a role in kidney injury, including the renin-angiotensin-aldosterone system (RAAS) [48-50], the nuclear factor- κB (NF- κB) [35-37,51], the transforming growth factor- β (TGF- β)/Smad [34,38,39,51,52], and the Wnt/ β -catenin signaling pathways [40,51]. Moreover, paricalcitol (19-nor- $1,25$ -dihydroxyvitamin D_2) is an active, nonhypercalcemic vitamin D analogue that shows similar biological activity, with fewer adverse effects and increased tolerance, as compared to those of vitamin D [53].

Antifibrotic effects of vitamin D and its analogues

Progressive renal fibrosis is the final manifestation of CKD leading to irreversible loss of nephrons and ESRD [54]. Fibroblast activation and proliferation are triggered by locally secreted fibrogenic cytokines such as TGF- β_1 , connective tissue growth factor, and monocyte chemotactic protein-1 (MCP-1) [55,56]. Among these fibrogenic cytokines, TGF- β signaling initiates renal tubular cell proapoptotic effects and the epithelial-to-mesenchymal transition (EMT) in tubular epithelial cells. The EMT is a process in which renal tubular cells lose their epithelial phenotype and acquire new features of the mesenchyme [57]. We demonstrated that TGF- β_1 expression increases in cyclosporine A (CsA)-treated rats, which was characterized by inflammatory cell infiltration, tubule-interstitial fibrosis, and glomerular sclerosis [38,58]. Paricalcitol treatment effectively prevented the TGF- β_1 -induced EMT and extracellular matrix accumulation, as evidenced by attenuated collagen deposition and fibrosis in CsA-treated rats. This result suggests that active vitamin D has antifibrotic effects [38]. We have also demonstrated that paricalcitol reduces expression of extracellular signal-regulated kinase 1/2 and c-Jun N-terminal kinase via TGF- β_1 activation

Table 1. Summary of studies investigating the effects of vitamin D and vitamin D analogues in experimental models of kidney disease

Study	Experimental model	Treatment	Main findings	Underlying mechanism
Park et al. [38]	Cyclosporine A induced nephropathy rat model	Paricalcitol	Attenuation of cyclosporine A induced nephropathy by suppression of inflammation, fibrosis, and apoptosis	Inhibition of NF- κ B, TGF- β 1/Smad and MAPK signaling
Tan et al. [33]	Unilateral ureteral obstruction rat model	Paricalcitol	Ameliorate renal interstitial fibrosis	Suppressed renal TGF- β 1 and its type I receptor expression and blocked the EMT
Schwarz et al. [39]	Subtotal nephrectomized rat	1,25(OH) $_2$ D $_3$	Decreased glomerular volume and albuminuria; improved glomerular sclerosis	Decreased cell proliferation; reduced vascular and tubular TGF- β 1 expression
Deb et al. [34]	Type 2 diabetic Lpr ^{db/db} mice model	Paricalcitol and losartan	Reduction of proteinuria and glomerulosclerosis	Decreased MCP-1, TGF- β 1, fibronectin, collagen IV, renin, and angiotensin I/II
He et al. [40]	Adriamycin nephropathy mice model	Paricalcitol	Prevented proteinuria and glomerulosclerosis	Suppressed TGF- β 1, CTGF, and Wnt/ β -catenin signaling
Park et al. [37]	Gentamicin induced nephropathy rat model	Paricalcitol	Restoration of renal function; inhibition of inflammation and fibrosis	Attenuation of NF- κ B, inflammatory cytokines, adhesion molecules, and TGF- β 1
Tan et al. [36]	Unilateral ureteral obstruction mice model	Paricalcitol	Inhibition of renal inflammation	Decreased RANTES, TNF- α , and NF- κ B
Sanchez-Nino et al. [35]	Type 1 diabetic streptozotocin rat model	Calcitriol and paricalcitol	Reduction of renal inflammation without reduced proteinuria	Decreased MCP-1, IL-6, and NF- κ B activation
Panichi et al. [42]	Anti-Thy-1.1 treated nephritis rat model	1,25(OH) $_2$ D $_3$	Reduction of glomerular hypercellularity, inflammation and apoptosis	Decreased His 48, ED-1, PCNA, and TUNEL-positive cell infiltration
Garcia et al. [41]	Unilateral ureteral obstruction rat model	Paricalcitol	Protection of mitochondrial injury	Decreased AT $_1$ R mRNA and NADPH activity
Park et al. [43]	Cisplatin-induced nephropathy rat model	Paricalcitol	Protection of fibrosis, apoptosis and proliferation	Inhibition of TGF- β 1, MAPK, p53. and p27
Suh et al. [44]	Gentamicin-induced nephropathy rat model	Paricalcitol	Antiapoptotic effect	Inhibition of Bax and JNK pathway
Xiao et al. [45]	PAN-induced rat model	1,25(OH) $_2$ D $_3$	Prevented podocyte apoptosis	Activation of PI3K/Akt and suppression of TGF- β 1

NF- κ B, nuclear factor- κ B; TGF- β , transforming growth factor- β ; MAPK, mitogen-activated protein kinase; EMT, epithelial-to-mesenchymal transition; MCP-1, monocyte chemotactic protein-1; CTGF, connective tissue growth factor; RANTES, regulated on activation, normal T cell expressed and secreted; TNF- α , tumor necrosis factor- α ; IL-6, interleukin-6; ED-1, anti-CD68 antibody; PCNA, proliferating cell nuclear antigen; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; AT $_1$ R, angiotensin II type 1 receptor; NADPH, nicotinamide adenine dinucleotide phosphate; JNK, jun N-terminal kinase; PAN, puromycin aminonucleoside; PI3K, phosphatidylinositol 3-kinase.

in CsA-treated rat kidneys [38]. Schwarz et al. [39] showed reduced albuminuria and suppression of glomerular sclerosis in subtotal nephrectomy rat models following treatment with $1,25(\text{OH})_2\text{D}_3$. Moreover, TGF- β 1 expression was attenuated in vascular and tubular cells in $1,25(\text{OH})_2\text{D}_3$ -treated rats [39]. In a mouse model of tubulointerstitial fibrosis that was induced by unilateral ureteral obstruction, paricalcitol reduced renal interstitial fibrosis and directly suppressed TGF- β 1-mediated tubular EMT [52]. In addition, in a model of type 2 diabetes, the combination of paricalcitol and losartan appeared to synergistically reduce the extracellular matrix protein in the glomerulus by suppressing TGF- β 1 and the RAAS [34].

A recent study showed that Wnt/ β -catenin signaling, which can be inhibited by paricalcitol treatment, plays a critical role in promoting proteinuria and renal fibrosis [40]. Interestingly, our *in vitro* data indicate that the β -catenin signaling pathway may mediate 4-hydroxy-2-hexenal (HHE)-induced renal tubular EMT, which can be effectively inhibited by paricalcitol-induced VDR/ β -catenin complex formation in human proximal tubular epithelial cells [51]. Paricalcitol inhibits β -catenin-mediated gene transcription by inducing VDR, resulting in sequestration of β -catenin transcriptional activity in the nuclei. Overall, the literature has demonstrated that active vitamin D and its analogues can ameliorate renal tubulointerstitial fibrosis or glomerulosclerosis.

Anti-inflammatory effects of vitamin D and its analogues

Renal inflammation is an essential pathological process in the evolution of CKD [59]. Several studies have shown the role of active vitamin D in the modulation of renal inflammation [37,38,41]. The anti-inflammatory properties of active vitamin D and its analogues may be attributed to their ability to suppress the NF- κ B pathway, a key transcription factor that is thought to mediate acute and chronic inflammation and fibrogenesis by regulating gene expression of cytokines, chemokines, and adhesion molecules (including interleukin-6, MCP-1, and tumor necrosis factor- α) [60]. In this context, we demonstrated that paricalcitol protects against kidney injury by blocking NF- κ B activity and reducing renal inflammation in CsA and gentami-

cin-induced renal injury [37,38]. Paricalcitol prevents upregulation of inflammatory cytokines and adhesion molecules in these experimental models. Tan et al. [36] showed that paricalcitol attenuates renal infiltration of inflammatory cells and inhibits tubular Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) expression, which is an important proinflammatory chemokine in the obstructed kidney. This anti-inflammatory effect of paricalcitol seems to be mediated by inducing the complex formation of VDR and NF- κ B p65 components, thereby reducing its binding to promoter regions of the target genes *in vitro* [36]. In addition, paricalcitol exerts an NF- κ B-dependent anti-inflammatory effect on HHE-induced renal injury by inactivating the mitogen-activated protein kinase pathway [51]. In animal models of diabetic nephropathy, treatment with calcitriol and paricalcitol reduces infiltration of inflammatory cells and NF- κ B activation in the glomerulus [35]. Similarly, administration of calcitriol attenuates glomerular hypercellularity and inflammatory infiltration in the anti-Thy-1.1 glomerulonephritis model [42]. Moreover, vitamin D may exert its anti-inflammatory influence through pleiotropic effects. Paricalcitol attenuates renin and angiotensin II expression in VDR knockout mice [50], suggesting that paricalcitol inhibits renal inflammation by suppressing the RAAS, as angiotensin II is a known proinflammatory stimulus. Taken together, these findings indicate that vitamin D and its analogues might be useful for treating inflammatory kidney diseases.

Antiapoptotic effects of vitamin D and its analogues

The decline in renal function during CKD results from renal cell death that precipitates functional and structural changes in the kidney [61]. Several common renal insults cause apoptosis in the kidney, including ischemia, toxic injury, radiation, and ureteral obstruction. Garcia et al. [41] reported that paricalcitol reduces the number of terminal deoxynucleotidyl transferase dUTP nick end labeling positive apoptotic cells and restores the high levels of angiotensin II type 1 receptor (AT₁R) mRNA and NADPH activity in mitochondrial fractions in an obstructed kidney. This observation indicates that the antiapoptotic and AT₁R-dependent protective effects occur at the mitochondrial level. Cisplatin is one of the most frequently used chemothera-

peutic agents against solid tumors. However, cisplatin may activate proapoptotic genes and repress antiapoptotic genes through transcriptional regulation [62]. We showed that paricalcitol attenuates the increased expression of phospho-p53 and p21, which initiate apoptotic processes in a cisplatin-induced rat model [43]. We also reported that an increased Bax/Bcl-2 ratio and the cleaved form of caspase-3, which are apoptotic markers, are reversed by paricalcitol treatment in gentamicin-induced kidney injury [44]. In addition, $1,25(\text{OH})_2\text{D}_3$ prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway [45]. Conversely, a recent study demonstrated that increased activation of CYP24A1 induced by vitamin D supplementation would accelerate kidney apoptosis through increased caspase-3 expression, particularly in a diabetic experimental mice model [63]. Although active vitamin D and its analogues appear to have an antiapoptotic effect in various experimental nephropathy models, more studies are required to reveal the disease-specific differences of vitamin D metabolism.

VITAMIN D DEFICIENCY AS A CONTRIBUTOR TO THE DEVELOPMENT OF CKD

High prevalence of vitamin D deficiency or insufficiency in patients with CKD has been well documented in recent epidemiological studies. Despite the lack of consensus on optimal vitamin D levels, the recent Kidney Disease Improving Global Outcomes guidelines suggest definitions of vitamin D deficiency as serum $25(\text{OH})\text{D}$ levels < 10 to 15 ng/mL (25 to 37 nmol/L) and insufficiency as ≥ 10 but < 20 to 32 ng/mL (50 to 80 nmol/L) [64]. However, many studies define serum $25(\text{OH})\text{D}$ levels < 20 ng/mL as deficient, 20 to 29.9 ng/mL as insufficient, and ≥ 30 ng/mL as sufficient [6,65,66]. In a large population-based study, a serum $1,25(\text{OH})_2\text{D}$ decline was observed during early stages of CKD, before significant elevation in PTH or hyperphosphatemia [67]. In addition, the prevalence of deficiency appears to increase with the progression of kidney disease [68]. Vitamin D deficiency is associated with the short life expectancy of patients with ESRD. Treatment with active vitamin D and its analogues improves survival in

the hemodialysis population [12,69-71]. Interestingly, a retrospective study showed that serum $25(\text{OH})\text{D}$ is an independent inverse predictor of kidney disease progression and death in patients with earlier stages of CKD [72]. These clinical data suggest that the association between vitamin D therapy and reduced mortality in patients with CKD is beyond the effects of vitamin D on PTH and mineral metabolism. In a recent meta-analysis of prospective observational studies, Pilz et al. [10] estimated a significant 14% decrease in the relative risk of mortality per 10 ng/mL increase in $25(\text{OH})\text{D}$ levels, indicating that higher vitamin D levels are associated with significantly improved survival in patients with CKD. However, there is no definite evidence for improved survival in patients with CKD being treated for low $25(\text{OH})\text{D}$ levels using natural or active vitamin D supplementation. Therefore, further randomized controlled trials are needed to determine whether correcting vitamin D deficiency affects the development of ESRD or mortality in patients with CKD.

Improvement of proteinuria and renal inflammation is considered an important determinant of progression of cardiovascular and renal diseases [73,74]. Several studies have shown a correlation between vitamin D deficiency and an increased degree of albuminuria [75,76]. A recent large randomized controlled trial, the Vitamin D receptor Activator for Albuminuria Lowering study, confirmed that adding 2 μg paricalcitol for RAAS blockade reduces albuminuria and blood pressure in patients with diabetic nephropathy [77]. Moreover, in a recent meta-analysis, active vitamin D therapy with either paricalcitol or calcitriol provided a significant reduction of proteinuria in patients with CKD in addition to current use of RAAS blockade [78]. That study showed that proteinuria decreased by 16% in patients treated with active vitamin D, and increased by 6% in patients receiving the control treatment.

Vitamin D deficiency has been associated with a higher risk of cardiovascular disease in patients with CKD and the general population [79]. Treatment with active vitamin D attenuates myocardial hypertrophy in experimental models of cardiac hypertrophy and prevents the development of heart failure [80,81]. The Paricalcitol Capsule Benefits in Renal Failure Induced Cardiac Morbidity study was performed to evaluate the beneficial effects of paricalcitol on left ventricular

Table 2. Summary of studies evaluating the effects of vitamin D and vitamin D analogues in patients with chronic kidney disease and dialysis

Study	Design	Study population	Intervention	Duration	Outcomes
Kalantar-Zadeh et al. [69]	Observational study	58,058 Patients undergoing hemodialysis	Paricalcitol or calcitriol and no treatment	2 yr	Administration of any dose of paricalcitol was associated with improved survival in time-varying models
Melamed et al. [70]	Prospective cohort study	1,007 Patients undergoing hemodialysis and peritoneal dialysis	Injectable vitamin D and no treatment	3 yr	Patients who received injectable vitamin D had a 26% lower mortality, as compared to those who did not receive vitamin D
Shoji et al. [71]	Prospective cohort study	242 Patients undergoing hemodialysis	Oral 1 alpha-hydroxyvitamin D ₃ (median of 0.5 µg) and no treatment	61 ± 23 mon	Alphacalcidol users showed a lower risk of death from cardiovascular disease than did nonusers
de Zeeuw et al. [77]	Randomized controlled trial (VITAL)	281 Patients with type 2 diabetes and albuminuria receiving ACEI/ARB	Placebo and paricalcitol 1 µg/day or 2 µg/day	24 wk	ACR from baseline to last evaluation was -3% in placebo group, -14% in the 1 µg paricalcitol group, and -20% in the 2 µg paricalcitol group
Liu et al. [86]	Randomized controlled trial	50 Patients with IgA nephropathy	Calcitriol 0.5 µg × 2 /week and no treatment	48 wk	24 Hours proteinuria from baseline to last evaluation was 21% in the control group and -19% in the calcitriol group
Thadhani et al. [82]	Randomized controlled trial (PRIMO)	227 Patients with CKD (stage 3, 4)	Paricalcitol 2 µg/day and placebo	48 wk	LVMI did not differ between paricalcitol and placebo groups, but cardiovascular-related hospitalizations were fewer in the paricalcitol group
Wang et al. [83]	Randomized controlled trial (OPERA)	60 Patients with CKD and LV hypertrophy (stage 3-5)	Paricalcitol 1 µg/day and placebo	52 wk	Change in LVMI was -2.59 g/m ² (-6.13 to 0.32) in paricalcitol vs. -4.85 g/m ² (-9.89 to 1.10) in placebo group (<i>p</i> = 0.40)
Alvarez et al. [85]	Randomized controlled trial	46 Patients with CKD (stage 2, 3)	Oral cholecalciferol (50,000 IU) and placebo	52 wk	High-dose cholecalciferol decreased serum MCP-1 by 12 weeks, but result was not maintained

VITAL, vitamin D receptor activator for albuminuria lowering study; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin II receptor blocker; ACR, albumin to creatinine ratio; IgA, immunoglobulin A; PRIMO, paricalcitol capsule benefits in renal failure induced cardiac morbidity study; CKD, chronic kidney disease; LV, left ventricular; LVMI, left ventricular mass index; MCP-1, monocyte chemotactic protein-1.

hypertrophy in patients with stage 3 and 4 CKD [82]. Changes in the left ventricular mass index (LVMI), the primary endpoint, were not significantly different between the paricalcitol-treated and control groups, but cardiovascular-related hospitalization was lower in the

paricalcitol-treated group. Similarly, a recent prospective randomized controlled trial showed that 52 weeks of treatment with oral paricalcitol did not regress LVMI or improve cardiac function in patients with stages 3 to 5 CKD [83]. One potential explanation for these results

is that paricalcitol may have increased FGF-23 expression, which directly induces cardiomyopathy in animal models [84].

In contrast, evidence is accumulating that noncardiovascular mortality (including infection and malignancies) also increases in patients with CKD. In the NHANES III cohort study of 3,011 patients with CKD who were not on dialysis, vitamin D levels < 15 ng/mL were associated with a significant increase in noncardiovascular mortality, as compared to those with vitamin D levels < 30 ng/mL [9]. In addition, nutritional vitamin D has anti-inflammatory and immune-regulating properties. A recent small randomized controlled trial study showed that oral cholecalciferol supplementation decreases serum MCP-1 in patients with early CKD [85]. Table 2 summarizes the studies that have examined the effects of vitamin D and its analogues on proteinuria, mortality, and cardiovascular disease in patients with CKD and those undergoing dialysis [69-71,77,82,83,85,86].

CONCLUSIONS

Progressive loss of kidney function is associated with considerable morbidity and mortality and is an important global health problem, given the high prevalence of CKD. The limitations of classic pharmacological therapy (i.e., RAAS blockade and statins) in delaying the progression of kidney injury have led to an increased interest in finding novel therapeutic agents that can stop the progression of kidney function loss or even improve kidney function. Treatment with active vitamin D or its analogues shows renoprotective effects by preventing fibrosis, apoptosis, and inflammation in various experimental models. Furthermore, vitamin D deficiency or insufficiency is a common condition in predialysis or dialysis patients with CKD, and serum levels of vitamin D appear to be inversely correlated with kidney function. Recent clinical studies report that the reduced proteinuria and mortality in CKD patients treated with active vitamin D is beyond the classical role of vitamin D in the maintenance of bone and mineral metabolism. Consequentially, vitamin D analogues, including paricalcitol, are emerging as potential treatment options for achieving better clinical outcomes in patients with advanced kidney disease and those who are undergoing

hemodialysis.

However, current guidelines only recommend vitamin D treatment in patients with moderate CKD accompanied by secondary hyperparathyroidism and vitamin D insufficiency. Many issues must still be resolved, including testing the different vitamin D analogues, assessing whether nutritional vitamin D truly increases survival, and determining whether clinical outcomes vary according to disease-specific vitamin D metabolism. Therefore, further investigations are required to answer these questions and, thereby, uncover the potential renoprotective mechanisms of vitamin D treatment for patients with CKD.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (2013R1A2A2A01067611) and by the National Research Foundation of Korea grant (MRC for Gene Regulation, 2011-0030132) funded by the Korean government (MSIP).

REFERENCES

1. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol* 2006;17:2034-2047.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39(2 Suppl 1):S1-S266.
3. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2003;41:1-12.
4. Shin SY, Kwon MJ, Park H, Woo HY. Comparison of chronic kidney disease prevalence examined by the chronic kidney disease epidemiology collaboration equation with that by the modification of diet in renal

- disease equation in Korean adult population. *J Clin Lab Anal* 2014 Feb 27 [Epub]. <http://dx.doi.org/10.1002/jcla.21688>.
5. Ruilope LM. Renal function and cardiovascular risk in hypertensive patients. *J Hypertens* 2005;23:1787-1788.
6. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;357:266-281.
7. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. *Am J Kidney Dis* 2005;45:1026-1033.
8. Urena-Torres P, Metzger M, Haymann JP, et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. *Am J Kidney Dis* 2011;58:544-553.
9. Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. *Kidney Int* 2009;76:977-983.
10. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. *Am J Kidney Dis* 2011;58:374-382.
11. Zheng Z, Shi H, Jia J, Li D, Lin S. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. *BMC Nephrol* 2013;14:199.
12. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. *J Am Soc Nephrol* 2005;16:1115-1125.
13. Mirkovic K, van den Born J, Navis G, de Borst MH. Vitamin D in chronic kidney disease: new potential for intervention. *Curr Drug Targets* 2011;12:42-53.
14. Holick MF. Resurrection of vitamin D deficiency and rickets. *J Clin Invest* 2006;116:2062-2072.
15. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. *Am J Physiol Renal Physiol* 2005;289:F8-F28.
16. Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. *Mol Cell Endocrinol* 2004;215:31-38.
17. Adams JS, Hewison M. Update in vitamin D. *J Clin Endocrinol Metab* 2010;95:471-478.
18. Ohyama Y, Ozono K, Uchida M, et al. Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 25-hydroxyvitamin D₃ 24-hydroxylase gene. *J Biol Chem* 1994;269:10545-10550.
19. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. *Kidney Int* 2006;69:33-43.
20. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. *Kidney Int* 2011;79:715-729.
21. Hilpert J, Wogensen L, Thykjaer T, et al. Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D₃ metabolism. *Kidney Int* 2002;62:1672-1681.
22. Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D₃. *Cell* 1999;96:507-515.
23. Leheste JR, Rolinski B, Vorum H, et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. *Am J Pathol* 1999;155:1361-1370.
24. Liu W, Yu WR, Carling T, et al. Regulation of gp330/megalin expression by vitamins A and D. *Eur J Clin Invest* 1998;28:100-107.
25. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *J Bone Miner Res* 2004;19:429-435.
26. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. *Endocrinology* 2005;146:5358-5364.
27. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. *Kidney Int* 2004;65:1943-1946.
28. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. *Kidney Int* 2003;64:2272-2279.
29. Tanaka Y, Deluca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. *Arch Biochem Biophys* 1973;154:566-574.
30. Kuro-o M. Klotho and the aging process. *Korean J Intern Med* 2011;26:113-122.
31. Usatii M, Rousseau L, Demers C, et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)₂D synthesis. *Kidney Int* 2007;72:1330-1335.

32. Hsu CH, Patel S. Uremic plasma contains factors inhibiting 1 alpha-hydroxylase activity. *J Am Soc Nephrol* 1992;3:947-952.
33. Tan X, Li Y, Liu Y. Therapeutic role and potential mechanisms of active vitamin D in renal interstitial fibrosis. *J Steroid Biochem Mol Biol* 2007;103:491-496.
34. Deb DK, Sun T, Wong KE, et al. Combined vitamin D analog and AT₁ receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. *Kidney Int* 2010;77:1000-1009.
35. Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. *Am J Physiol Renal Physiol* 2012;302:F647-F657.
36. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. *J Am Soc Nephrol* 2008;19:1741-1752.
37. Park JW, Bae EH, Kim IJ, et al. Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats. *Am J Physiol Renal Physiol* 2010;298:F301-F313.
38. Park JW, Bae EH, Kim IJ, et al. Paricalcitol attenuates cyclosporine-induced kidney injury in rats. *Kidney Int* 2010;77:1076-1085.
39. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25(OH)₂ vitamin D₃ on glomerulosclerosis in subtotaly nephrectomized rats. *Kidney Int* 1998;53:1696-1705.
40. He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. *J Am Soc Nephrol* 2011;22:90-103.
41. Garcia IM, Altamirano L, Mazzei L, et al. Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy. *Am J Physiol Renal Physiol* 2012;302:F1595-F1605.
42. Panichi V, Migliori M, Taccola D, et al. Effects of 1,25(OH)₂D₃ in experimental mesangial proliferative nephritis in rats. *Kidney Int* 2001;60:87-95.
43. Park JW, Cho JW, Joo SY, et al. Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. *Eur J Pharmacol* 2012;683:301-309.
44. Suh SH, Lee KE, Park JW, et al. Antiapoptotic effect of paricalcitol in gentamicin-induced kidney injury. *Korean J Physiol Pharmacol* 2013;17:435-440.
45. Xiao H, Shi W, Liu S, et al. 1,25-Dihydroxyvitamin D₃ prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. *Am J Nephrol* 2009;30:34-43.
46. Makibayashi K, Tatematsu M, Hirata M, et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. *Am J Pathol* 2001;158:1733-1741.
47. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D₃ decreases podocyte loss and podocyte hypertrophy in the subtotaly nephrectomized rat. *Am J Physiol Renal Physiol* 2004;286:F526-F533.
48. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. *Kidney Int* 2008;74:1394-1402.
49. Zhang Y, Deb DK, Kong J, et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT₁ receptor antagonist. *Am J Physiol Renal Physiol* 2009;297:F791-F801.
50. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D₃ is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 2002;110:229-238.
51. Kim CS, Joo SY, Lee KE, et al. Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inflammation and epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. *PLoS One* 2013;8:e63186.
52. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. *J Am Soc Nephrol* 2006;17:3382-3393.
53. Drueke TB. Which vitamin D derivative to prescribe for renal patients. *Curr Opin Nephrol Hypertens* 2005;14:343-349.
54. Okada H, Kalluri R. Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. *Curr Mol Med* 2005;5:467-474.
55. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. *J Clin Invest* 2003;112:1486-1494.
56. Rampanelli E, Rouschop K, Teske GJ, Claessen N, Leemans JC, Florquin S. CD44v3-v10 reduces the profibrotic effects of TGF-beta1 and attenuates tubular injury in the early stage of chronic obstructive nephropathy. *Am J Physiol Renal Physiol* 2013;305:F1445-F1454.
57. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. *J Am Soc Nephrol* 2010;21:1247-

- 1253.
58. Yoon HE, Yang CW. Established and newly proposed mechanisms of chronic cyclosporine nephropathy. *Korean J Intern Med* 2009;24:81-92.
59. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. *J Am Soc Nephrol* 2000;11:152-176.
60. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. *Kidney Int* 2001;59:415-424.
61. Havasi A, Borkan SC. Apoptosis and acute kidney injury. *Kidney Int* 2011;80:29-40.
62. Jiang M, Wei Q, Wang J, et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. *Oncogene* 2006;25:4056-4066.
63. Tourigny A, Charbonneau F, Xing P, et al. CYP24A1 exacerbated activity during diabetes contributes to kidney tubular apoptosis via caspase-3 increased expression and activation. *PLoS One* 2012;7:e48652.
64. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl* 2009;(113):S1-S130.
65. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr* 2006;84:18-28.
66. Nigwekar SU, Bhan I, Thadhani R. Ergocalciferol and cholecalciferol in CKD. *Am J Kidney Dis* 2012;60:139-156.
67. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. *Kidney Int* 2007;71:31-38.
68. Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. *Clin J Am Soc Nephrol* 2009;4:1523-1528.
69. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. *Kidney Int* 2006;70:771-780.
70. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. *Kidney Int* 2006;70:351-357.
71. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. *Nephrol Dial Transplant* 2004;19:179-184.
72. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. *Kidney Int* 2009;75:88-95.
73. Holtkamp FA, de Zeeuw D, de Graeff PA, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. *Eur Heart J* 2011;32:1493-1499.
74. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. *J Am Soc Nephrol* 2007;18:1540-1546.
75. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). *Am J Kidney Dis* 2007;50:69-77.
76. Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. *J Ren Nutr* 2011;21:295-302.
77. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. *Lancet* 2010;376:1543-1551.
78. de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. *J Am Soc Nephrol* 2013;24:1863-1871.
79. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. *Circulation* 2008;117:503-511.
80. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)₂ vitamin D₃ and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. *J Clin Invest* 1996;97:1577-1588.

81. Bae S, Yalamarti B, Ke Q, et al. Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. *Cardiovasc Res* 2011;91:632-639.
82. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. *JAMA* 2012;307:674-684.
83. Wang AY, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD: the OPERA trial. *J Am Soc Nephrol* 2014;25:175-186.
84. Faul C, Amaral AP, Oskoue B, et al. FGF23 induces left ventricular hypertrophy. *J Clin Invest* 2011;121:4393-4408.
85. Alvarez JA, Zughaier SM, Law J, et al. Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. *Eur J Clin Nutr* 2013;67:264-269.
86. Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. *Am J Kidney Dis* 2012;59:67-74.